EGF and non-small cell lung carcinoma: As an immunotherapy targeting epidermal growth factor (EGF), several clinical trials have been carried out in patients with advanced non-small-cell lung cancer (NSCLC), and the Cuban regulatory agency has approved CIMAvax-EGF as maintenance therapy after first-line treatment [15,16,17].